Workflow
丰倍生物今日申购 顶格申购需配市值11万元
Zheng Quan Shi Bao Wang·2025-10-27 01:28

Core Points - The company Fengbei Bio is opening its subscription today, with a total issuance of 35.90 million shares, of which 11.48 million shares are for online subscription at a price of 24.49 yuan per share, resulting in a price-to-earnings ratio of 30.47 times [2][3] - The company primarily focuses on the comprehensive utilization of waste oil resources, with a secondary emphasis on oil chemical products [2] Issuance Information - Stock Code: 603334, Stock Abbreviation: Fengbei Bio, Subscription Code: 732334, Issuance Price: 24.49 yuan, Issuance P/E Ratio: 30.47 times, Reference Industry P/E Ratio: 64.73 [3] - Subscription Date: October 27, 2025, Online Issuance Quantity: 11.48 million shares, Total Issuance Quantity: 35.90 million shares, Maximum Subscription Quantity per Account: 11,000 shares, Minimum Subscription Quantity: 500 shares [3] - To participate in the maximum subscription, an investor needs to have a market value of 110,000 yuan [2][3] Fundraising Purpose - The company plans to invest 75 million yuan in new projects, including the annual production of 300,000 tons of oleic acid methyl ester, 10,000 tons of industrial-grade mixed oil, 50,000 tons of agricultural microbial agents, and 10,000 tons of compound microbial fertilizers [3] - An additional 25 million yuan will be allocated to supplement working capital [3] Key Financial Indicators - Total Assets: 12.37 billion yuan in 2024, up from 10.51 billion yuan in 2023 and 9.38 billion yuan in 2022 [3] - Net Assets: 7.56 billion yuan in 2024, compared to 6.30 billion yuan in 2023 and 5.13 billion yuan in 2022 [3] - Operating Revenue: 19.48 billion yuan in 2024, an increase from 17.28 billion yuan in 2023 and 17.09 billion yuan in 2022 [3] - Net Profit: 1.24 billion yuan in 2024, slightly down from 1.30 billion yuan in 2023 and 1.33 billion yuan in 2022 [3] - Basic Earnings per Share: 1.15 yuan in 2024, down from 1.21 yuan in 2023 and 1.26 yuan in 2022 [3] - Weighted Return on Equity: 17.91% in 2024, down from 22.43% in 2023 and 30.57% in 2022 [3]